Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid (Q33928694)

30 July 2017

1 reference

title

Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid (English)

1 reference

30 July 2017

main subject

gram-positive bacteria

0 references

0 references

1 reference

1 reference

2

Sobel JD

1 reference

30 July 2017

Lundstrom TS

1

1 reference

30 July 2017

language of work or name

1 reference

1 June 2000

1 reference

30 July 2017

number of pages

12

1 reference

Infectious Disease Clinics of North America

inferred from page(s)

published in

1 reference

30 July 2017

volume

14

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

463-474

1 reference

Agranulocytosis related to vancomycin therapy

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Persistent staphylococcal bacteremia in an intravenous drug abuser

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

1 reference

7 January 2021

Prevention of bacterial endocarditis. Recommendations by the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

A review of the safety profile of teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Emergence of vancomycin-resistant enterococci in New York City

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Vancomycin concentrations in infected and noninfected human bone

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Microbiological properties of teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

1 reference

7 January 2021

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Evaluation of a method for initiating vancomycin therapy: experience in 205 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Clinical pharmacokinetics of vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Once weekly intraperitoneal therapy for gram-positive peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Diversity among multidrug-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Peritoneal Transport of Vancomycin during Peritoneal Dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

RP 59500, a streptogramin derivative, is effective in murine listeriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Vancomycin and the red-man syndrome: pharmacodynamics of histamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Clinical pharmacokinetics of teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

The in-vitro activity of linezolid (U-100766) and tentative breakpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

A prospective study of adverse reactions associated with vancomycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Intraventricular vancomycin for treatment of shunt-associated ventriculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Oral vancomycin for antibiotic-associated pseudomembranous colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Vancomycin concentration in human tissues —preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

1 reference

7 January 2021

Dosage recommendations for teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970258-0

7 January 2021

10.1016/S0891-5520(05)70258-0

Identifiers

DOI

1 reference

30 July 2017

1 reference